Please assess the completion status of the following clinical trial:

Trial Title: Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* P. falciparum mono-infection~* Fever (axillary temperature ≥37.5⁰C) or history of fever in preceding 48 hours~* Age \>1 years (≥ 18 years at the Ethiopia site)~* G6PD normal as defined by the Biosensor (SD Biosensor, ROK) at ≥70% of the adjusted male median (AMM) for each site~* Written informed consent~* Able to comply with all study procedures and timelines~Exclusion Criteria:~* General danger signs or symptoms of severe malaria~* Anaemia, defined as Hb \<8g/dl~* Pregnant women as determined by Urine β-HCG pregnancy test~* Breast feeding women~* Known hypersensitivity to any of the drugs given~* Regular use of drugs with haemolytic potential~* Blood transfusion within the last 4 months

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PQ7 (Type: EXPERIMENTAL): high dose primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
- standard care (Type: NO_INTERVENTION): As per national guidelines for P. falciparum treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).